Loading
Finch Therapeutics Group, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Graf Susan E, was filed 09 Jun 2023.
Insider Decl.
31
Thresholds
n/a
Buy Volume
€26M
6 ops. · all time
Sell Volume
€36,528
6 ops. · all time
Since the insiders bought
- -95.6%Entry US$323.70 · Close at T+365 US$14.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$10.35
Analyst consensus
Income statement
RevenueUS$107k
EBITDA-US$32.5M-30357% margin
Net income-US$74.8M-69863.6% margin
Valuation
P/Book1.2x
Beta0.97
Balance sheet & cash
Market capUS$16.6M
Total debtUS$30.1M
Free Cash Flow-US$31.5M
Debt / Equity204%
Profitability & ownership
ROE-67.3%
ROA-21.9%
% institutions0.0%
Last declaration on 10 June 2024
Declarations31 total
383 shares0Common StockSEC:0000950170-24-071496:1
384 shares0Common StockSEC:0000950170-24-071496:0
3,750 shares0Common StockSEC:0000950170-24-064850:0
1,600 shares@ US$2.610.3% of flowCommon StockSEC:0000950170-24-038657:1
6,642 shares@ US$2.5776.3% of flowCommon StockSEC:0000950170-24-038657:0
1,470 shares@ US$3.6423.7% of flowCommon StockSEC:0000950170-23-066155:0
5,010 shares@ US$0.27100.0% of flowCommon StockSEC:0000899243-23-015177:0
Canonical exit: 7 Sept 2023 (T+90)
4,619 shares@ US$0.3824.1% of flowCommon StockSEC:0000899243-23-005985:0
3,636 shares@ US$1.3975.9% of flowCommon StockSEC:0000899243-22-034125:0
3,636 shares@ US$1.39100.0% of flowCommon StockSEC:0000899243-22-034122:0
35,000 shares0Common StockSEC:0000899243-22-022621:0
35,000 shares0Common StockSEC:0000899243-22-022623:0
63,850 shares@ US$10.18100.0% of flowCommon Stock, $0.001 par value per shareSEC:0001567619-21-022453:0
Canonical exit: 20 Mar 2022 (T+90)
735,294 shares@ US$17.00100.0% of flowCommon StockSEC:0000950142-21-001061:1
Canonical exit: 21 Jun 2021 (T+90)
102,941 shares@ US$17.00100.0% of flowCommon StockSEC:0001209191-21-023073:3
Canonical exit: 21 Jun 2021 (T+90)
88,235 shares@ US$17.0098.4% of flowCommon StockSEC:0001209191-21-023075:4
Canonical exit: 21 Jun 2021 (T+90)
882,351 shares@ US$17.0095.6% of flowCommon StockSEC:0001209191-21-023074:6
Canonical exit: 21 Jun 2021 (T+90)
300,948 sharesCommon StockSEC:0001209191-21-023073:1
90,378 sharesCommon StockSEC:0001209191-21-023073:2
1,150,481 sharesCommon StockSEC:0001209191-21-023074:5
11,906,147 sharesCommon StockSEC:0000950142-21-001061:0
141,928 sharesCommon StockSEC:0001209191-21-023073:0
894,955 sharesCommon StockSEC:0001209191-21-023075:0
141,928 sharesCommon StockSEC:0001209191-21-023075:1
297,178 sharesCommon StockSEC:0001209191-21-023075:2
25 of 31 declarations
About Finch Therapeutics Group, Inc.
In March 2021, four insiders at Finch Therapeutics Group, Inc. filed purchases on the same day, EUR 25,768,773 in all. The largest are by director Nicholas Haft, EUR 12,570,123, Crestovo Investor LLC, filed as Director, EUR 10,475,124, and director Domenic J. Ferrante, EUR 1,466,515. These three trades make up most of the EUR 26.3 million of purchases on record, which hold 6 purchases, median EUR 1,361,763.
A US healthcare and pharma company listed on Nasdaq with a known market capitalisation of USD 16,619,658, Finch has 31 filings published from March 25, 2021 to June 10, 2024, from seven filers, and none in the last twelve months. The 6 sales weigh only EUR 36,528, median EUR 5,035. The largest, EUR 15,786, is by director Jeffery A. Smisek on March 28, 2024; Marc Blaustein, Chief Operating Officer, and Joseph Vittiglio, Chief Business & Legal Officer, each sold EUR 5,168 on October 21, 2022.
Read moreShow less
Jeffery A. Smisek is the top filer with 11 filings, 3 of them sales. The year 2021 holds 19 of the 31 filings. There are also 17 filings of another nature and 2 grants. Filings are published a median of 2 days after the trade.
